[ad_1]
That is what Reuters reports.
The order comes after Dr. Anthony Fauci, the United States’ leading infection control expert, said Wednesday that the drug has good effects against covid-19.
– Remdesivir has an obvious, significant and positive effect in reducing the course of the disease. This shows that Remdesivir can block the virus, Fauci said Wednesday.
By then, the American pharmaceutical giant Gilead, which has manufactured Remdesivir, had reported that a large-scale trial of the drug yielded positive results.
The company developed Remdesivir at the time to treat Ebola patients, but it didn’t work. Now that Remdesivir can be shown to have a positive effect on the coronavirus, the drug may pave the way for the development of better drugs, he believes.
Fauci.
He compares the discovery to the fight to develop anti-HIV drugs in the 1980s. At the time, he even participated in the race.
“This is similar to the situation 34 years ago in 1986 when we struggled to find drugs to treat HIV, but we had nothing,” he said.
“It is a door opener that we now have the ability to treat patients,” said Fauci.
Seriously ill at first
The leading infection control expert in the United States, who is also a top adviser to President Donald Trump’s work in the fight against the coronavirus, says Gilead is now in dialogue with the US medical authorities. USA To get approval to use Remdesivir
to the neediest patients.
It means seriously ill patients, as the study only included patients who are already in the hospital, and not patients with mild or early symptoms, Fauci said. Approval will be a much more complicated matter
to use the drug more generally, he added.
Trump has said the United States study is a very positive start and turn in the fight against coronavirus.
Disappointing study
Early Wednesday, a study of Remdesivir was published in the acclaimed magazine The Lancet. The study concludes that “there is no significant clinical benefit” with the use of Remdesivir in the treatment of patients with a crown.
The study was conducted by China-Japan Friendship Hospital and Capital Medical University in China. 237 covid-19 patients in Wuhan, China participated in the study. Half of them got Remdesivir. The other half was a control group.
and received regular antibiotic treatment.
[ad_2]
